Particle.news
Download on the App Store
10 ARTICLES
·
2h ago

India Clears Ozempic for Type 2 Diabetes as Novo Nordisk Prepares Launch

High initial prices are expected until semaglutide’s patent expires in March 2026, opening the door to cheaper generics.

With Ozempic Hitting India, We Answer All Your Top Questions About The Much Anticipated Weight Loss Drug - From Cost To Risks (Credits: iStock)
Drugs such as Ozempic make people crave food less and have now turned into a weight-loss drug.
Which is better for diabetes, Ozempic or Mounjaro?

Overview

  • The CDSCO approved semaglutide injection (Ozempic) on September 26 for adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise, and it will be available only by prescription.
  • Novo Nordisk says it aims to make the once‑weekly injection available in India soon, but the company has not disclosed pricing.
  • The Indian approval covers blood sugar control in diabetes rather than the higher‑dose weight‑loss indication used in some other markets, and experts warn against off‑label or black‑market use.
  • Clinicians emphasize medical supervision due to common gastrointestinal side effects and rarer risks such as pancreatitis, gallbladder issues, kidney problems and thyroid concerns.
  • Market watchers note competition from Eli Lilly’s tirzepatide (Mounjaro), and reports suggest comparable therapies currently cost roughly ₹14,000–₹26,000 per month while generics could lower costs after 2026.